Skip to main content
AGMBAgomAb Therapeutics NVHold4.8·$5.45
HoldModerate Confidence
Investment thesis

AgomAb screens as a high-asymmetry biotech with 120% analyst-target upside, but quality metrics sit below the engine's investable floor and momentum is only marginally positive, so the exit-position call stands despite the headline valuation gap.

Thesis pillars

  • Value Trap Leverage Margin→Stable
  • Asymmetric Upside To Target→Stable
  • Sub Floor Business Quality→Stable
  • +2 more pillars — see the Why tab for full reasoning

Pillars as of Jul 5, 2026· older than 90 days

Full reasoning →

Open full analysis

AgomAb Therapeutics NV (AGMB) Stock Analysis

Falling Knife setup

HoldQualityModerate Confidence

Healthcare · Biotechnology

Hold if already holding. Not a fresh buy at $5.45, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $37.67 vs price $5.45 — ratio 6.9×). Rejected, falling back to technical TP.; Market cap $268M below $400M minimum.

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted... Read more

$5.45+67.7% Upside to targetScore 4.8/10#181 of 240 Biotechnology
QualityF-score4 / 9FCF yield—
Stop $5.23Resistance target $9.14A.R:R 0.0:1
Analyst consensus$37.67+591.1%6 analysts with price targets
$9.14Resistance target
$5.45price
$37.67mean
$60

Hold if already holding. Not a fresh buy at $5.45, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $37.67 vs price $5.45 — ratio 6.9×). Rejected, falling back to technical TP.; Market cap $268M below $400M minimum. Chart setup: Death cross, below all MAs, RSI 30, MACD bearish. Market cap $268M below $400M minimum. Not in investable universe. Score 4.8/10, moderate confidence.

Passes 6/9 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.

news + 30-day 8-K events · 5-min refresh

Recent developments

No fresh coverage since Nov 6, 2026

Recent Developments — AgomAb Therapeutics NV

Latest item Nov 6, 2026 · Generated 2026-11-22T12:02:07Z.

Thesis

Rewards
No bull case signals
Risks
DATA_ISSUE: analyst_target_implausible (raw $37.67 vs price $5.45 — ratio 6.9×). Rejected, falling back to technical TP.
Market cap $268M below $400M minimum

Key Metrics

P/E (TTM)—
P/E (Fwd)-2.7
Mkt Cap$268M
EV/EBITDA-2.2
Profit Mgn0.0%
ROE—
Rev Growth—
Beta—
DividendNone
Analysts with ratings14

Quality Signals

Piotroski F4/9MoatNarrow

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

2 floor-breakers

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Volume
0.5
Obv
1.0
Ma Position
1.5
Macd
2.9
Rsi
3.0
Capitulation risk (RSI 30, below 200MA)Volume distribution (falling OBV)Below 200-MA, MA slope flat

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Gross Margin
0.0
Operating Margin
0.0
Net Margin
0.0
Piotroski F
4.4
Current Ratio
5.0
Moat
5.5
Quality concerns
GatesMomentum 1.8<4.5Death cross (50MA < 200MA)A.R:R UPSIDE_EXHAUSTED (upside=0.0%)Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY NO DATESEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARFalling KnifeSuitability: Speculative
RSI
30 · Oversold
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $5.39Resistance $9.33

Price Targets

$5
$9
A.R:R0.0:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeSteady

Risk Alerts

! DATA_ISSUE: analyst_target_implausible (raw $37.67 vs price $5.45 — ratio 6.9×). Rejected, falling back to technical TP.
! Market cap $268M below $400M minimum
! momentum at 1.8 (below the engine's 4.5 threshold)

Earnings

We could not retrieve earnings history for AGMB.
The company may be recently listed, pre-revenue, or its beat/miss record wasn't available from our source this run. Earnings signals feed the Growth and Catalyst score dimensions — absence here doesn't affect other dimensions.

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is AGMB stock a buy right now?

Hold if already holding. Not a fresh buy at $5.45, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $37.67 vs price $5.45 — ratio 6.9×). Rejected, falling back to technical TP.; Market cap $268M below $400M minimum. Chart setup: Death cross, below all MAs, RSI 30, MACD bearish. Market cap $268M below $400M minimum. Not in investable universe. Resistance target $9.14 (+67.7%), stop $5.23 (−4.2%), A.R:R 0.0:1. Score 4.8/10, moderate confidence.

What is the AGMB stock price target?

Resistance target: $9.14 (+67.7% upside). Resistance target $9.14 (+67.7%), stop $5.23 (−4.2%), A.R:R 0.0:1. Stop-loss: $5.23.

What are the risks of investing in AGMB?

DATA_ISSUE: analyst_target_implausible (raw $37.67 vs price $5.45 — ratio 6.9×). Rejected, falling back to technical TP.; Market cap $268M below $400M minimum.

Is AGMB overvalued or undervalued?

AgomAb Therapeutics NV trades at a P/E of N/A (forward -2.7). TrendMatrix value score: 5.0/10. Verdict: Hold.

What do analysts say about AGMB?

14 analysts rate AGMB, with a consensus score of 4.2/5. 6 analysts publish price targets averaging $38.

What does AgomAb Therapeutics NV do?AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for...

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.

Related stocks: ZVRA (Zevra Therapeutics, Inc.) · PHAT (Phathom Pharmaceuticals, Inc.) · ADRX (ADARx Pharmaceuticals, Inc.) · HRMY (Harmony Biosciences Holdings, I) · MGTX (MeiraGTx Holdings plc)
Home › Stocks › AGMB

Latest news

Latest News

Fiscal.ai16d ago
Fiscal.ai17d ago
Fiscal.ai30d ago
Benzinga40d agoProduct
Benzinga45d agoProduct
Benzinga52d ago
Benzinga52d agoProduct
Benzinga52d ago
Benzinga52d agoProduct
Benzinga89d agoAnalyst
Benzinga89d ago
Benzinga95d agoAnalyst
Benzinga95d ago
Benzinga108d agoEarnings
Benzinga122d ago